Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
Autor:
Cortés-Martín, Adrián
; Plaza-Diaz, Julio
Fecha:
28/01/2025Revista / editorial:
World Journal of GastroenterologyCitación:
Cortés-Martín A, Plaza-Diaz J. Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders. World J Gastroenterol 2025; 31(4): 101436Tipo de Ítem:
Articulo Revista Indexada
Resumen:
This article comments on the work by Soresi and Giannitrapani. The authors have stated that one of the most novel and promising treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) is the use of glucagon-like peptide 1 receptor agonists, especially when used in combination therapy.
However, despite their notable efficacy, these drugs were not initially designed to target MASLD directly. In a groundbreaking development, the Food and Drug Administration has recently approved resmetirom, the first treatment specifically aimed at reducing liver fibrosis in metabolic-associated steatohepatitis.
Resmetirom, an orally administered, liver-directed thyroid hormone beta-selective agonist, acts directly on intrahepatic pathways, enhancing its therapeutic potential and marking the beginning of a new era in the treatment of MASLD. Furthermore, the integration of lifestyle modifications into liver disease management is an essential component that should be considered and reinforced. By incorporating dietary changes and regular physical exercise into treatment, patients may achieve improved outcomes, reducing the need for pharmacological interventions and/or improving treatment efficacy. As a complement to medical therapies, lifestyle factors should not be overlooked in the broader strategy for managing MASLD.
Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(es)
Estadísticas de uso
Año |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Vistas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
78 |
Descargas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
66 |
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Effect of a Novel Food Rich in Miraculin on the Intestinal Microbiome of Malnourished Patients with Cancer and Dysgeusia
Plaza-Diaz, Julio; Brandimonte-Hernández, Marco; López-Plaza, Bricia; Ruiz-Ojeda, Francisco Javier; Álvarez-Mercado, Ana Isabel; Arcos-Castellanos, Lucía; Feliú-Batlle, Jaime; Hummel, Thomas; Palma-Milla, Samara; Gil, Angel (Nutrients, 10/01/2025)Background/Objectives: Dysgeusia contributes to malnutrition and worsens the quality of life of patients with cancer. Despite the different strategies, there is no effective treatment for patients suffering from taste ... -
The Role of the Microbiome and of Radiotherapy-Derived Metabolites in Breast Cancer
Herrera-Quintana, Lourdes; Vázquez-Lorente, Héctor; Costa Silva, Rafael Cardoso Maciel; Olivares-Arancibia, Jorge; Reyes-Amigo, Tomás; Barreto Pires, Bruno Ricardo; Plaza-Diaz, Julio (Cancers, 2024)The gut microbiome has emerged as a crucial player in modulating cancer therapies, including radiotherapy. In the case of breast cancer, the interplay between the microbiome and radiotherapy-derived metabolites may enhance ... -
Celiac Disease: Beyond Diet and Food Awareness
Herrera-Quintana, Lourdes; Navajas-Porras, Beatriz; Vázquez-Lorente, Héctor; Hinojosa-Nogueira, Daniel; Corrales-Borrego, Francisco J.; Lopez-Garzon, Maria; Plaza-Diaz, Julio (MDPI, 2025)Celiac disease is attributable to a combination of genetic predisposition and exposure to dietary gluten, with immune system involvement. The incidence is increasing globally, and the societal economic burden of celiac ...